And I predict that 2025 will be another momentous year for Summit. Summit already owned the license to market ivonescimab in ...

The Danish pharma giant posted impressive data for amycretin one month after the disappointing readout of CagriSema.

There's just one task left for the Detroit Lions to clinch the No. 1 seed in the NFC. After the Minnesota Vikings beat the Green Bay Packers on Sunday, 27-25, in Week 17 of the NFL season, the ...

Viking Therapeutics struggles with FDA approval and scaling up. Find out why VKTX stock’s path remains uncertain, despite its ...

Viking Therapeutics Inc (VKTX) stock saw a modest uptick, ending the day at $34.94 which represents a slight increase of $0.89 or 2.61% from the prior close of $34.05. The stock opened at $33.85 and ...

Jefferies analyst Roger Song maintained a Buy rating on Viking Therapeutics (VKTX – Research Report) yesterday and set a price target of ...

Viking Therapeutics, Inc. offers promising advances in obesity and liver diseases, despite a recent stock drop over GLP-1 market concerns. Click for my VKTX update.

Viking Therapeutics Inc (VKTX) stock saw a modest uptick, ending the day at $32.87 which represents a slight increase of $0.22 or 0.67% from the prior close of $32.65. The stock opened at $32.87 and ...

The stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY ...

ONS-5010 (bevacizumab-vikg) was found to be noninferior to ranibizumab for neovascular age-related macular degeneration at week 12.

One of the hottest growth areas in the healthcare landscape these days is the obesity drug market because of a class of drugs ...

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.